ESMO/Linkedin
Aug 8, 2025, 18:45
Two Major Hurdles of CAR-T Cell Therapies – ESMO
European Society for Medical Oncology (ESMO) shared a post on LinkedIn:
“CAR-T cell therapies have been highly successful for treating B cell malignancies and have also recently shown potential for the treatment of solid tumours.
However, two major hurdles have slowed their development and widespread use: the toxicity/efficacy balance and logistic aspects linked to a complex manufacturing process.
Read the opinion by Philippe Cassier in the ESMO Daily Reporter.”
More posts featuring ESMO.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 21:29
Aug 8, 2025, 21:08
Aug 8, 2025, 20:54
Aug 8, 2025, 20:18
Aug 8, 2025, 20:03
Aug 8, 2025, 19:51
Aug 8, 2025, 19:34